Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Randomized Phase II Trial of Pentostatin, Cyclophosphamide, and Rituximab with or without Concurrent Avastin for Previously Untreated B-Chronic Lymphocytic Leukemia (CLL)

Tait D. Shanafelt, MD, Betsy R. LaPlant, MS, Timothy G Call, MD, Daniel Nikcevich, MD PhD, Jose F. Leis, MD PhD, Wei Ding, MD PhD, Adam Pettinger, Daniel L. Van Dyke, PhD, Diane F. Jelinek, Curtis A. Hanson, MD, Neil E. Kay, MD

Blood (2014) 124 (21): 4673.

https://doi.org/10.1182/blood.V124.21.4673.4673

Published: 2014

Journal Articles

Phase II Clinical Trial of Denileukin Diftitox In Combination with Rituximab In Previously Untreated Follicular B-Cell Non-Hodgkin's Lymphoma

Stephen M Ansell, MD, PhD, Hui Tang, PhD, Grzegorz S. Nowakowski, MD, Daniel Nikcevich, MD, PhD, Garth D Nelson, Charles Erlichman, MD, Thomas E Witzig, MD, North Central Cancer Treatment Group

Blood (2010) 116 (21): 2862.

https://doi.org/10.1182/blood.V116.21.2862.2862

Published: 2010

Journal Articles

PET Scan Results of NCCTG N0489: Epratuzumab and Rituximab in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone Chemotherapy (ER-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma.

Ivana N. Micallef, MD, Matthew J. Maurer, Thomas E. Witzig, MD, Daniel Nikcevich, MD, PhD, Paul Kurtin, MD, Michael W. Cannon, MD, Patrick J. Flynn, MD, Gamini S. Soori, MD, Val Lowe, MD, Gregory Wiseman, MD

Blood (2009) 114 (22): 137.

https://doi.org/10.1182/blood.V114.22.137.137

Published: 2009

Journal Articles

A Randomized Comparison of Standard Weekly Epoetin Alfa to Every-3-Week Epoetin Alfa and Every-3-Week Darbepoetin Alfa: A Study of the Mayo Clinic Cancer Research Consortium (MCCRC).

David P Steensma, MD, Shaker R. Dakhil, MD, Paul J Novotny, MS, Jeff A Sloan, PhD, David B Johnson, MD, Daniel M Anderson, MD, Bassam I Mattar, MD, Dennis F Moore, Jr., MD, Daniel Nikcevich, MD, PhD, Charles L Loprinzi, MD

Blood (2009) 114 (22): 3008.

https://doi.org/10.1182/blood.V114.22.3008.3008

Published: 2009

Journal Articles

Safety Trial of NK Cell Enhanced Donor Lymphocyte Infusions from a 3-5/6 HLA Matched Family Member Following Nonmyeloablative Allogeneic Stem Cell Transplantation

David A. Rizzieri, MD, Robert Storms, Ph.D, Daniel Nikcevich, MD, PhD, Bercedis Peterson, Ph.D, Debashish Misra, MD, Christine Apple, Megan Baker, Cristina Gasparetto, MD, Mitchell Horwitz, MD, John Chute, MD, Ashley Morris, PharmD., Nelson J. Chao, MD

Blood (2008) 112 (11): 342.

https://doi.org/10.1182/blood.V112.11.342.342

Published: 2008

NARROW

Randomized Phase II Trial of Pentostatin, Cyclophosphamide, and Rituximab with or without Concurrent Avastin for Previously Untreated B-Chronic Lymphocytic Leukemia (CLL)

Phase II Clinical Trial of Denileukin Diftitox In Combination with Rituximab In Previously Untreated Follicular B-Cell Non-Hodgkin's Lymphoma

PET Scan Results of NCCTG N0489: Epratuzumab and Rituximab in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone Chemotherapy (ER-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma.

A Randomized Comparison of Standard Weekly Epoetin Alfa to Every-3-Week Epoetin Alfa and Every-3-Week Darbepoetin Alfa: A Study of the Mayo Clinic Cancer Research Consortium (MCCRC).

Safety Trial of NK Cell Enhanced Donor Lymphocyte Infusions from a 3-5/6 HLA Matched Family Member Following Nonmyeloablative Allogeneic Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Randomized Phase II Trial of Pentostatin, Cyclophosphamide, and Rituximab with or without Concurrent Avastin for Previously Untreated B-Chronic Lymphocytic Leukemia (CLL)

Phase II Clinical Trial of Denileukin Diftitox In Combination with Rituximab In Previously Untreated Follicular B-Cell Non-Hodgkin's Lymphoma

PET Scan Results of NCCTG N0489: Epratuzumab and Rituximab in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone Chemotherapy (ER-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma.

A Randomized Comparison of Standard Weekly Epoetin Alfa to Every-3-Week Epoetin Alfa and Every-3-Week Darbepoetin Alfa: A Study of the Mayo Clinic Cancer Research Consortium (MCCRC).

Safety Trial of NK Cell Enhanced Donor Lymphocyte Infusions from a 3-5/6 HLA Matched Family Member Following Nonmyeloablative Allogeneic Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only